Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
- Conditions
- Leukemia
- Registration Number
- NCT00009698
- Lead Sponsor
- Children's Oncology Group
- Brief Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation for acute myeloid leukemia.
- Detailed Description
OBJECTIVES: I. Determine the maximum tolerated dose of interleukin-2 after autologous bone marrow transplantation in pediatric patients with acute myeloid leukemia. II. Determine toxic effects of this regimen in these patients.
OUTLINE: This is a dose escalation study. Patients receive interleukin-2 (IL-2) subcutaneously on days 1-7, 9-14, and 16-22. On days 8 and 15, patients receive IL-2 IV over 2 hours. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 6-9 patients receive escalating doses of IL-2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 2 of 9 patients experience dose-limiting toxicity. Patients are followed every 6 months for 4 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 6-27 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To determine the maximum tolerated dose (MTD) of IL-2 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (119)
University of Alabama at Birmingham Comprehensive Cancer Center
πΊπΈBirmingham, Alabama, United States
University of South Alabama Medical Center
πΊπΈMobile, Alabama, United States
MBCCOP - Gulf Coast
πΊπΈMobile, Alabama, United States
Arizona Cancer Center
πΊπΈTucson, Arizona, United States
Arkansas Children's Hospital
πΊπΈLittle Rock, Arkansas, United States
University of Arkansas for Medical Sciences
πΊπΈLittle Rock, Arkansas, United States
University of California San Diego Cancer Center
πΊπΈLa Jolla, California, United States
Lucile Packard Children's Hospital at Stanford
πΊπΈPalo Alto, California, United States
Sutter Cancer Center
πΊπΈSacramento, California, United States
University of California Davis Medical Center
πΊπΈSacramento, California, United States
Scroll for more (109 remaining)University of Alabama at Birmingham Comprehensive Cancer CenterπΊπΈBirmingham, Alabama, United States